Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics is viewed favorably because its deramiocel program has meaningful clinical traction in Duchenne muscular dystrophy, with HOPE-3 showing a 4.55% difference versus placebo at 12 months and about a 54% slowing of upper-limb function loss. The FDA’s acceptance of a major BLA amendment and extension of the PDUFA to 11/22 support a more constructive benefit-risk debate, while the 24-month HOPE-3 OLE data and potential presentation on 10/3 could further validate durability and sharpen the narrative. Financially, the company ended 2Q:26 with $238 million in cash, and the model still sees >$2B peak revenue potential, implying a favorable risk-reward setup despite prior investor pessimism.

Capricor Therapeutics is facing a fragile investment case because Deramiocel’s core evidence base is still limited to a small Phase II dataset, open-label follow-up, and an external natural history comparator, which leaves meaningful uncertainty around safety, efficacy, and whether topline Phase HOPE-3 data will be enough. The recent AdCom on 7/29/26 was negative, the FDA may still view the package as insufficient for full approval, and ex-U.S. pathways remain untested, while commercialization is further burdened by quarterly infusion logistics, payer acceptance of a premium per-dose price, and outsourced execution. Financially, delays threaten the expected near-term non-dilutive cash infusion of >$230M and could force dilutive financing, while active litigation with its U.S. commercialization partner adds another layer of execution and economics risk.